Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer

Ryan D Chow; Ramy Sedhom; Ronac Mamtani

doi:10.1001/jamaoncol.2025.4566

Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer

JAMA Oncol. 2026 Jan 1;12(1):104-106. doi: 10.1001/jamaoncol.2025.4566.

Authors

Ryan D Chow¹, Ramy Sedhom^{1

2}, Ronac Mamtani¹

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia.
² Penn Center for Cancer Care Innovation, Abramson Cancer Center, Penn Medicine, Philadelphia, Pennsylvania.

PMID: 41231504
PMCID: PMC12616528 (available on 2026-11-13)
DOI: 10.1001/jamaoncol.2025.4566

No abstract available

Plain language summary

This retrospective cohort study examines the association of upfront treatment with enfortumab vedotin plus pembrolizumab with clinical outcomes for patients with advanced urothelial cancer.